California, Japan and Germany-based Rakuten Aspyrian, a developer of precision-targeted cancer therapies, has raised $150 million in Series C financing. The lead investor was Hiroshi Mikitani, CEO of Rakuten Inc.
Source: Press Release
California, Japan and Germany-based Rakuten Aspyrian, a developer of precision-targeted cancer therapies, has raised $150 million in Series C financing. The lead investor was Hiroshi Mikitani, CEO of Rakuten Inc.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: